EU Not Planning To Renew Vaccine Contracts With AstraZeneca, J&J In 2022 - Reports

EU Not Planning to Renew Vaccine Contracts With AstraZeneca, J&J in 2022 - Reports

The European Commission has decided not to extend the contracts with AstraZeneca and Johnson & Johnson on supplies of their coronavirus vaccines over reports of blood clotting side effects, Italian newspaper La Stampa reported on Wednesday, citing a health ministry source

ROME (Pakistan Point News / Sputnik - 14th April, 2021) The European Commission has decided not to extend the contracts with AstraZeneca and Johnson & Johnson on supplies of their coronavirus vaccines over reports of blood clotting side effects, Italian newspaper La Stampa reported on Wednesday, citing a health ministry source.

The bloc will reportedly instead focus on procuring RNA-based vaccines, such as those developed by Pfizer and Moderna.

On Tuesday, the US food and Drug Administration recommended suspending the use of Johnson & Johnson vaccine over six cases of blood clotting. Following the statement, the US company announced that it would delay its planned vaccine rollout in Europe.

AstraZeneca's vaccine sparked blood clot concerns last month. Despite the EU regulator's report confirming that post-inoculation thrombosis was a "very rare" side effect, a number of countries restricted its use.